MY202368A - Methods of treating ulcerative colitis - Google Patents

Methods of treating ulcerative colitis

Info

Publication number
MY202368A
MY202368A MYPI2020004942A MYPI2020004942A MY202368A MY 202368 A MY202368 A MY 202368A MY PI2020004942 A MYPI2020004942 A MY PI2020004942A MY PI2020004942 A MYPI2020004942 A MY PI2020004942A MY 202368 A MY202368 A MY 202368A
Authority
MY
Malaysia
Prior art keywords
ulcerative colitis
methods
treating ulcerative
treatment
treating
Prior art date
Application number
MYPI2020004942A
Other languages
English (en)
Inventor
Lawrence Tuttle Jay
Milch Catherine
Ann Krueger Kathryn
William Friedrich Stuart
Benedict Canavan James
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY202368A publication Critical patent/MY202368A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MYPI2020004942A 2018-03-30 2019-03-28 Methods of treating ulcerative colitis MY202368A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
PCT/US2019/024633 WO2019191464A1 (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis

Publications (1)

Publication Number Publication Date
MY202368A true MY202368A (en) 2024-04-24

Family

ID=66429483

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020004942A MY202368A (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis

Country Status (29)

Country Link
US (2) US12152072B2 (https=)
EP (2) EP4327866B1 (https=)
JP (4) JP7119114B2 (https=)
KR (1) KR102552693B1 (https=)
CN (1) CN111936165A (https=)
AU (2) AU2019243283C1 (https=)
BR (1) BR112020018099A2 (https=)
CA (1) CA3095297A1 (https=)
DK (2) DK3773715T3 (https=)
EA (1) EA202091989A1 (https=)
ES (2) ES3063700T3 (https=)
FI (2) FI3773715T3 (https=)
HR (2) HRP20240904T1 (https=)
HU (1) HUE067445T2 (https=)
IL (2) IL277514B2 (https=)
LT (2) LT4327866T (https=)
MA (2) MA67901B1 (https=)
MD (1) MD3773715T2 (https=)
MX (1) MX2020010269A (https=)
MY (1) MY202368A (https=)
PL (2) PL3773715T3 (https=)
PT (2) PT3773715T (https=)
RS (2) RS67806B1 (https=)
SG (1) SG11202009526RA (https=)
SI (1) SI3773715T1 (https=)
TW (2) TWI837532B (https=)
UA (1) UA128578C2 (https=)
WO (1) WO2019191464A1 (https=)
ZA (1) ZA202005388B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CA3170677A1 (en) * 2020-02-14 2021-08-19 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
JP2024501900A (ja) * 2021-01-06 2024-01-16 アッヴィ・インコーポレイテッド クローン病及び潰瘍性大腸炎を処置する方法
EP4340875A1 (en) * 2021-05-20 2024-03-27 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP2024521748A (ja) * 2021-05-28 2024-06-04 イーライ リリー アンド カンパニー 潰瘍性大腸炎に関与する遺伝子の抗il-23p19抗体調節
WO2023095000A1 (en) * 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
US20240199734A1 (en) * 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
KR20250156783A (ko) 2023-03-10 2025-11-03 일라이 릴리 앤드 캄파니 궤양성 결장염을 치료하는 방법
CN121443635A (zh) * 2023-06-16 2026-01-30 信达生物医药科技(杭州)有限公司 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2026060205A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006265002B2 (en) * 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
US20110212104A1 (en) * 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PE20141162A1 (es) * 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
CA3092551A1 (en) * 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody

Also Published As

Publication number Publication date
EP4327866A2 (en) 2024-02-28
JP7331219B2 (ja) 2023-08-22
AU2019243283B2 (en) 2023-07-27
JP2025020134A (ja) 2025-02-12
HUE067445T2 (hu) 2024-10-28
AU2023248103B2 (en) 2026-02-05
IL277514B2 (en) 2024-11-01
JP7119114B2 (ja) 2022-08-16
HRP20260275T1 (hr) 2026-04-10
TWI744617B (zh) 2021-11-01
IL312807B1 (en) 2025-02-01
PT4327866T (pt) 2026-02-17
ES3063700T3 (en) 2026-04-20
TW202206104A (zh) 2022-02-16
SI3773715T1 (sl) 2024-06-28
BR112020018099A2 (pt) 2020-12-22
IL312807B2 (en) 2025-06-01
TW201946657A (zh) 2019-12-16
US20210032325A1 (en) 2021-02-04
IL312807A (en) 2024-07-01
EP4327866A3 (en) 2024-03-20
ES2983809T3 (es) 2024-10-24
CA3095297A1 (en) 2019-10-03
IL277514B1 (en) 2024-07-01
RS67806B1 (sr) 2026-03-31
ZA202005388B (en) 2025-05-28
DK3773715T3 (da) 2024-05-27
PL3773715T3 (pl) 2024-08-19
DK4327866T3 (da) 2026-02-23
HRP20240904T1 (hr) 2024-10-11
KR20200128101A (ko) 2020-11-11
PT3773715T (pt) 2024-05-27
US12152072B2 (en) 2024-11-26
EP4327866B1 (en) 2025-12-10
JP7571225B2 (ja) 2024-10-22
FI3773715T3 (fi) 2024-05-30
JP2023166388A (ja) 2023-11-21
LT3773715T (lt) 2024-06-25
RS65661B1 (sr) 2024-07-31
US20250034243A1 (en) 2025-01-30
EP3773715B1 (en) 2024-05-08
MA52216A (fr) 2021-02-17
CN111936165A (zh) 2020-11-13
AU2019243283A1 (en) 2020-09-24
UA128578C2 (uk) 2024-08-21
AU2019243283C1 (en) 2024-05-02
AU2023248103A1 (en) 2023-11-09
TWI837532B (zh) 2024-04-01
MA67901B1 (fr) 2026-02-27
WO2019191464A1 (en) 2019-10-03
JP2021517156A (ja) 2021-07-15
SG11202009526RA (en) 2020-10-29
MX2020010269A (es) 2020-11-06
KR102552693B1 (ko) 2023-07-07
LT4327866T (lt) 2026-03-10
FI4327866T3 (fi) 2026-02-18
MD3773715T2 (ro) 2024-10-31
IL277514A (en) 2020-11-30
EA202091989A1 (ru) 2021-01-13
JP2022169562A (ja) 2022-11-09
EP3773715A1 (en) 2021-02-17
PL4327866T3 (pl) 2026-04-20
MA52216B1 (fr) 2024-07-31
NZ767902A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
ZA202005388B (en) Methods of treating ulcerative colitis
MA39906A (fr) Polythérapies pour le traitement du cancer
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX2017011374A (es) Método de tratamiento de cáncer asociado con una mutación de ras.
MX2017010150A (es) Bacterias probioticas recombinantes.
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
PH12018501443A1 (en) Methods of administering hepcidin
SG10201804034QA (en) Methods for treating hypotension
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
MX388593B (es) Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MX2019004804A (es) Tratamiento para el prurigo nodula.
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
MX382608B (es) Tratamiento del prurito urémico.
ZA202108094B (en) Mirikizumab for use in a method of treating crohn's disease
MX2019014291A (es) Metodo de tratamiento.
MY207627A (en) Methods of treating psoriasis